This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Gene Logic, Inc.. Active years: 2004.
Company Filing History:
Years Active: 2004
Title: Mark B Rabin: Innovator in Genetic Research
Introduction
Mark B Rabin is a notable inventor based in Rockville, MD (US). He has made significant contributions to the field of genetics, particularly in relation to the BRCA1 gene, which is crucial for understanding genetic susceptibility to breast and ovarian cancer. His work has implications for both genetic testing and therapeutic interventions.
Latest Patents
Mark B Rabin holds a patent for the invention titled "Coding sequence haplotype of the human BRCA1 gene." This invention is directed to isolated coding sequences and the protein sequences they code for. The coding sequence for the BRCA1(omi4) gene is provided along with the protein sequence it codes for. The BRCA1(omi4) sequence is utilized for identifying individuals with an increased genetic susceptibility to breast or ovarian cancer due to inherited mutations in their BRCA1 gene. Additionally, this invention relates to methods of performing gene therapy using the isolated BRCA1(omi4) coding sequence and protein replacement therapy with the BRCA1(omi4) protein.
Career Highlights
Mark B Rabin is associated with Gene Logic, Inc., where he has been able to apply his expertise in genetic research. His work has contributed to advancements in understanding genetic markers and their implications for health.
Collaborations
Some of his notable coworkers include Antonette C P Allen and Tracy Staton Angelly. Their collaborative efforts have likely enhanced the research environment and fostered innovation within the company.
Conclusion
Mark B Rabin's contributions to genetic research, particularly through his patent on the BRCA1 gene, highlight his role as an innovator in the field. His work not only aids in identifying genetic risks but also paves the way for potential therapeutic solutions.